The product being offered
Are there approved medicines for this?
The Food and Drug Administration (FDA) is the U.S. federal drug agency.
Semaglutide (Wegovy) and tirzepatide (Zepbound) have FDA-approved weight-care uses as of September 2026.
Ask which product is being proposed and which use is on the prescription.
Source · FDA drug application records
Can a pharmacy make a cheaper version?
Here, a copy is a made-to-order drug that closely matches a ready-made one.
In September 2026, neither semaglutide injections nor tirzepatide injections appear on FDA’s national shortage list.
One pharmacy having no stock does not mean a shortage has been listed nationwide.
As of September 2026, the law restricts regularly making these copies for named patients. An exception needs a change that the prescriber judges to make a significant difference for that patient. A cheaper price by itself does not count.
Source · FDA on supply and compounded copies
Does adding a vitamin settle the issue?
As of September 2026, FDA says a compounded weight drug may remain a copy even after a vitamin is added.
For the named patient, the prescriber must decide and record why the change makes a significant difference.
Ask what health need the change would meet for you, and why the ready-made drug would not meet it. A blend name or a claim that the vitamin makes it better does not explain that.
Source · FDA’s example of a vitamin-added copy
What does Florida require for weight care?
Florida’s Board of Medicine weight-care rule calls for a first check of your health, a full health history, an exam and any needed tests, as of September 2026.
That rule allows telemedicine, meaning care from a distance; it does not insist on an in-person visit.
Ask how the service would carry out those steps and review your health at later visits.